Company Overview and News
Inovio Pharmaceuticals, (INO - Free Report) has initiated a phase II study to evaluate the efficacy of its pipeline candidate VGX-3100 on adult men and women with human papilloma virus (HPV)-related anal dysplasia. This will be the third indication that VGX-3100 will be evaluated for. It is already being evaluated to treat HPV-related vulvar and anal precancers.
Fibrogen announced positive updated results from its phase 2b PRAISE study in treating patients with idiopathic pulmonary fibrosis.
AstraZeneca (AZN - Free Report) announced that the FDA has approved Lokelma (sodium zirconium cyclosilicate) formerly known as ZS-9, for the treatment of hyperkalemia in adults. Hyperkalemia is a serious condition characterized by high levels of potassium in the blood and Lokelma is a highly selective, oral potassium-removing agent.
Good morning and good afternoon. Welcome, ladies and gentlemen, to AstraZeneca’s Q1 Results Analyst Conference Call. Before I hand over the call to Pascal Soriot of AstraZeneca, I’d like to read the Safe Harbor statement.
This week AstraZeneca (AZN - Free Report) , Novartis (NVS - Free Report) and Eli Lilly (LLY - Free Report) announced regulatory and pipeline updates on line extensions of their marketed drugs. While AstraZeneca’s asthma drug Fasenra failed to meet the primary endpoint in a late-stage study evaluating it for an expanded indication — chronic obstructive pulmonary disease (“COPD”); Lilly’s migraine candidate galcanezumab met the same in a late-stage study, evaluating it for another indication — prevention of episodic cluster headache.
The following slide deck was published by AstraZeneca Group plc in conjunction with their 2018 Q1 earnings call.
Friday, May 18, 2018 With a highly anticipated royal wedding on the docket for this weekend — if you’ve been living under a rock, Prince Harry will be wed to American actress and humanitarian activist Meghan Markle Saturday, mid-day in England and very early in the a.m. U.S. time — we thought it might be worthwhile to take a peek at the performance of British-oriented stocks. Especially now that the Brexit decision voted on nearly 2 years ago is finally being enacted, we may be seeing different forecasts for some of our favorite English stocks.
With a highly anticipated royal wedding on the docket for this weekend — if you’ve been living under a rock, Prince Harry will be wed to American actress and humanitarian activist Meghan Markle Saturday, mid-day in England and very early in the a.m. U.S. time — we thought it might be worthwhile to take a peek at the performance of British-oriented stocks. Especially now that the Brexit decision voted on nearly 2 years ago is finally being enacted, we may be seeing different forecasts for some of our favorite English stocks.
AstraZeneca plc (AZN - Free Report) missed the Zacks Consensus Estimate for both earnings and sales in the first quarter of 2018 hit by declining sales of its cholesterol drug, Crestor. The Swiss pharma giant maintained its previously issued outlook for 2018. The stock declined more than 2% in pre-market trading on Friday.
The overall bioscience market rallied strongly today. Many equities under our coverage moved significantly further north.
Investors are always looking for stocks that are poised to beat at earnings season and AstraZeneca PLC (AZN - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report. That is because AstraZeneca is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings—with the most up-to-date information possible—is a pretty good indicator of some favorable trends underneath the surface for AZN in this report.
Novel medicine (indoximod) has an interesting mechanism of action. It’s most likely to deliver synergistic efficacy and safety (in combinations with other anticancer molecules).
An opportunity to post a comeback still exists because there is a second identical phase 3 study treating patients with chronic obstructive pulmonary disease.
Armo BioSciences (NASDAQ:ARMO), a Bay Area immuno-oncology company, agreed to be acquired by Eli Lilly (NYSE:LLY) in a $1.6 billion transaction. Last year, Armo raised $67 million in a 2017 Series C-1 funding from China investors. Four months ago, Armo completed a $128 million IPO at a $500 million valuation. Lilly offered to pay $50 per share for Armo, a three-fold increase from the IPO price and a 67% jump from its previous close, to acquire the company with its portfolio of immuno-oncology candidates.
This week Eli Lilly (LLY - Free Report) announced an all-cash deal tobuy immuno-oncology biotech, ARMO Biosciences, Inc. (ARMO - Free Report) . J&J’s (JNJ - Free Report) multiple myeloma drug Darzalex gained FDA approval for combination use in first-line setting while Roche (RHHBY - Free Report) announced a couple of regulatory/pipeline updates on its PD-L1 inhibitor, Tecentriq. AstraZeneca (AZN - Free Report) sold rights to a schizophrenia product and its PARP inhibitor, Lynparza gained marketing approval in the EU.
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
2018-05-21 - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...